Once daily isotretinoin composition

WO2024236523A1PCT designated stage expired Publication Date: 2024-11-21SUN PHARMACEUTICAL INDUSTRIES LTD
View PDF 6 Cites 0 Cited by

Patent Information

Application Number
PCT/IB2024/054760
Authority / Receiving Office
WO · WO
Patent Type
Applications
Current Assignee / Owner
Priority Date
2023-05-16
Filing Date
2024-05-16
Publication Date
2024-11-21

Smart Images

  • Figure PCTXMLIB-APPB-I000001
    Figure PCTXMLIB-APPB-I000001
  • Figure PCTXMLIB-APPB-I000002
    Figure PCTXMLIB-APPB-I000002
  • Figure 00000016_0000
    Figure 00000016_0000
Patent Text Reader

Abstract

The present invention relates to a method of treating acne comprising administering to the subject, a pharmaceutical composition comprising micronized isotretinoin; wherein, the composition is administered once daily to the subject under a fasting state, at a dose of about 0.4 mg / kg to about 1.6 mg / kg of isotretinoin. In particular, the composition further comprises one or more surfactants; and one or more co-solvents.
Need to check novelty before this filing date? Find Prior Art

Description

ONCE DAILY ISOTRETINOIN COMPOSITIONFIELD OF THE INVENTION

[0001] The present invention relates to a method of treating acne comprising administering to the subject, a pharmaceutical composition comprising micronized isotretinoin; wherein, the composition is administered once daily to the subject under a fasting state, at a dose of about 0.4 mg / kg to about 1.6 mg / kg of isotretinoin. In particular, the composition further comprises one or more surfactants; and one or more co-solvents.BACKGROUND OF THE INVENTION

[0002] Isotretinoin is a retinoid (also known as 13-cis retinoic acid). Owing to its low water solubility, the oral bioavailability of isotretinoin is low. PCT Publication No. WO 00 / 25772 discloses that the presently marketed formulation of isotretinoin, i.e., Accutane®, contains isotretinoin at a mean particle size of about 100 μm resulting in only 20% oral bioavailability.

[0003] U.S. Pat. Nos. 7,435,427 and 8,367,102 cover the marketed formulation of Absorica®. These patents disclose capsules comprising a semi-solid suspension of isotretinoin containing at least two lipidic excipients, one having an HLB value equal to or greater than 10 and the other being an oily vehicle. These patents are based on the use of the “Lidose® technology” to provide a formulation of isotretinoin with enhanced bioavailability.

[0004] U.S. Pat. Nos. 9,700,535 and 9,750,711 cover the marketed formulation of Absorica LD®. These patents discloses a low dose oral pharmaceutical composition comprising micronized isotretinoin and a pharmaceutically acceptable excipient, wherein said composition, when administered orally, provides an equivalent efficacy at a lower dose of isotretinoin in comparison to the marketed Absorica® capsules. The patent discloses that the composition have reduced food effect, in particular no food effect and may be administered without any regard to meals.

[0005] The dose of Absorica® is 0.5 to 1 mg / kg / day given in two divided doses without regard to meals for 15 to 20 weeks. Absorica LD®is 0.4 to 0.8 mg / kg / daygiven in two divided doses without regard to meals for 15 to 20 weeks. The label of Absorica® and Absorica LD®specifically state “The safety and effectiveness of once daily dosing with ABSORICA / ABSORICA LD has not been established and is not recommended.”

[0006] Lidose technology and micronization have markedly improved the gastrointestinal absorption of oral isotretinoin, allowing for administration without food and for a lower recommended daily dose.

[0007] The present inventors have surprisingly found that a once daily administration of the pharmaceutical composition comprising micronized isotretinoin to subjects in fasting state provides enhanced bioavailability, better subject compliance and shows comparable safety and efficacy to the marketed twice-daily formulations of isotretinoin, e.g. Accutane®, Absorica® and Absorica LD ®.SUMMARY OF THE INVENTION

[0008] The present invention provides a method of treating acne comprising administering to the subject a pharmaceutical composition comprising:micronized isotretinoin having D90 value of not more than 30 microns,one or more surfactants having HLB value of 10 or greater; andone or more co-solventswherein, the composition is, administered once daily to the subject under a fasting state, at a dose of about 0.4 mg / kg to about 1.6 mg / kg of isotretinoin.

[0009] In one aspect, the subjects are ≥12 years of age.

[0010] In another aspect, the pharmaceutical composition is administered to the subjects at patient weight based dosing

[0011] In another aspect, the pharmaceutical composition is administered to the subjects at the dose of isotretinoin as mentioned below:Body WeightTotal Daily Dosage (mg)0.4 mg / kg0.8 mg / kg1.6 mg / kg40 kg16326450 kg20408060 Kg24489670 Kg285611280 Kg326412890 Kg3672144

[0012] In another aspect, the pharmaceutical composition is administered once daily to the subjects for 15-20 weeks. Preferably, the pharmaceutical composition is administered once daily to the subjects for 20 weeks.

[0013] In another aspect, the present invention provides a method of treating acne, wherein the acne is selected from the group consisting of recalcitrant nodular acne, acne vulgaris, acne rosacea, acne conglobata, acne fulminans, gram-negative folliculitis, and pyoderma faciale. More preferably, the acne is recalcitrant nodular acne.

[0014] In yet another aspect, the once daily treatment results in ≥90% reduction in nodular lesion count in >95% of patients. More preferably, the once daily treatment results in ≥90% reduction in nodular lesion count in 100% of patients. The results were assesses at 24 weeks.

[0015] In another aspect, the once daily treatment results in median decrease in total facial nodule lesion count (NLC) of at least 5. More preferably, the once daily treatment results in median decrease in total facial nodule lesion count (NLC) of at least 5.5. More preferably, the once daily treatment results in median decrease in total facial nodule lesion count (NLC) of 6. The results were assessed at 24 weeks.

[0016] In another aspect, the once daily treatment results in IGA score of clear or almost clear (IGA 0 / 1) in ≥90% of patients. More preferably, the once daily treatment results in IGA score of clear or almost clear (IGA 0 / 1) in ≥95% of patients. The results were assessed at 24 weeks.

[0017] In another aspect, the once daily treatment results in at least 90% reduction in inflammatory lesion count. More preferably, the once daily treatment results in at least 95% reduction in inflammatory lesion count. The results were assessed at 24 weeks.

[0018] In another aspect, the once daily treatment results in at least 90% reduction in non-inflammatory lesion count. More preferably, the once daily treatment results in at least 95% reduction in non-inflammatory lesion count. The results were assessed at 24 weeks.

[0019] In one aspect, the particle size distribution of isotretinoin in the composition is such that D90 is less than 30 μm, less than 25 μm, less than 20 μm, less than 15 μm, or less than 10 μm. Preferably, the particle size distribution of isotretinoin is such that D50, less than 20 μm, less than 15 μm, less than 10 μm, or less than 5 μm. More preferably, the particle size distribution of isotretinoin is such that D50 is less than 15 μm.

[0020] In another aspect, the particle size distribution of isotretinoin is such that D10 is less than 10 μm, less than 8 μm, less than 7 μm, less than 5 μm, or less than 2 μm. More preferably, the particle size distribution of isotretinoin is such that D10 is less than 7 μm.

[0021] In one aspect, the surfactant in the pharmaceutical composition is selected from the group comprising of polysorbates prepared from lauric, palmitic, stearic, and oleic acid; polyoxyethylene monoesters; polyethoxylated castor oils; polyethylene glycol glycerides; Vitamin E TPGS; dioctyl sodium sulfosuccinate; sodium lauryl sulfate; poloxamers; and mixtures thereof. The surfactant is present in an amount of about 1% w / w to about 99% w / w by total weight of the composition. More preferably, the surfactant is present in an amount of about 30% w / w to about 80% w / w by total weight of the composition.

[0022] In yet another aspect, the co-solvent in the pharmaceutical composition is selected from the group consisting of propylene glycol, polypropylene glycol, polyethylene glycols, diethyleneglycol monoethyl ether, glyceryl caprylate, capric / caprylic glyceride, and mixtures thereof.

[0023] In yet another aspect, the pharmaceutical composition further comprises an antioxidant. The antioxidant in the composition is selected from the group consisting of butylated hydroxy anisole, butylated hydroxy toluene, tocopherol, ascorbyl palmitate, ascorbic acid, sodium metabisulfite, sodium sulfite, sodium thiosulfate, propyl gallate, and mixtures thereof.

[0024] In another aspect, the composition is in the form of a dispersion which is further filled into capsules.

[0025] In another aspect, the present invention provides a method of treating of acne comprising administering to the subject a pharmaceutical composition comprising:micronized isotretinoin having D90 value of not more than 30 microns,one or more surfactants having HLB value of 10 or greater; andone or more co-solventswherein, the composition is administered once daily to the subject under a fasting state, at a dose of about 0.4 mg / kg to about 1.6 mg / kg of isotretinoin for 20 weeks, and

[0026] wherein, the treatment results into Investigator Global Assessment (IGA) score of clear or almost clear (IGA 0 / 1) in at least 95% of patients when assessed at 24 weeks.BRIEF DESCRIPTION OF THE FIGURES:

[0027] illustrates the median (%) change from baseline of nodular lesion count through Week 24.

[0028] illustrates percentage of subjects achieving IGA 0 / 1 through Week 24.

[0029] illustrates percentage reduction from baseline in lesion counts through Week 24.DETAILED DESCRIPTION OF THE INVENTION

[0030] It should be noted that, the singular forms “a,” “an,” and, “the” include plural referents unless the context clearly dictates otherwise. Thus, for example, reference to “an excipient” includes reference to one or more of such excipients, and reference to “the carrier” includes reference to one or more of such carriers.

[0031] As used herein, “drug,” “active agent,”, “pharmaceutically active agent,” “therapeutically active agent” and “pharmaceutical,” may be used interchangeably to refer to an agent or substance that has measurable specified or selected physiologic activity when administered to a subject in a significant or effective amount. These terms of art are well known in the pharmaceutical and medicinal arts.

[0032] As used herein, the term “treatment” when used in conjunction with the administration of isotretinoin, refers to the administration of isotretinoin to subjects who are either asymptomatic or symptomatic. The terms “treat,” “treating,” and “treatment,” in the context of treating a disease or disorder, are meant to include alleviating or abrogating a disorder, disease, or condition, or one or more of the symptoms associated with the disorder, disease, or condition; or to slowing the progression, spread or worsening of a disease, disorder or condition or of one or more symptoms thereof or it can be prophylactic treatment, i.e. to prevent or reduce the occurrence or severity of the symptoms.

[0033] As used herein, the terms “formulation” and “composition” are used interchangeably and refer to a mixture of two or more compounds, elements, or molecules. When any of the above terms are modified by the term “oral” such terms refer to compositions, formulations, or dosage forms formulated and intended for oral administration to subjects.

[0034] As used herein, “subject” or “patient” refers to any human or non-human animal (e.g., a male human, female human, fetus, pregnant female, child, or the like) that may benefit from the administration of a drug composition or method of this invention. In one specific aspect, a subject is a human.

[0035] The term “oral administration” represents any method of administration in which an active agent can be administered by swallowing, chewing, or sucking or drinking an oral dosage form.

[0036] A used herein connection with numerical values, the terms “approximately” and “about” mean ±10% of the indicated value, including the indicated value.

[0037] In one or more aspect of the present disclosure provides, a method of treating of acne comprising administering to the subject a pharmaceutical composition comprising:micronized isotretinoin having D90value of not more than 30 microns,one or more surfactants having HLB value of 10 or greater; andone or more co-solventswherein, the composition is, administered once daily to the subject under a fasting state, at a dose of about 0.4 mg / kg to about 1.6 mg / kg of isotretinoin;

[0038] In one of the embodiment of the present invention, the subjects treated for acne are of ≥12 years of age.

[0039] In another aspect, the pharmaceutical composition is administered to the subjects at patient weight based dosing

[0040] In another aspect, the pharmaceutical composition is administered to the subjects at the dose of isotretinoin as mentioned below:Body WeightTotal Daily Dosage (mg)0.4 mg / kg0.8 mg / kg1.6 mg / kg40 kg16326450 kg20408060 Kg24489670 Kg285611280 Kg326412890 Kg3672144

[0041] In another aspect, the pharmaceutical composition is administered once daily to the subjects for 15-20 weeks. Preferably, the pharmaceutical composition is administered once daily to the subjects for 20 weeks.

[0042] In another aspect, the present invention provides a method of treating acne, wherein the acne is selected from the group consisting of recalcitrant nodular acne, acne vulgaris, acne rosacea, acne conglobata, acne fulminans, gram-negative folliculitis, and pyoderma faciale. More preferably, the acne is recalcitrant nodular acne.

[0043] In yet another aspect, the once daily treatment results in ≥90% reduction in nodular lesion count in >95% of patients. More preferably, the once daily treatment results in ≥90% reduction in nodular lesion count in 100% of patients. The results were assessed at 24 weeks.

[0044] In another aspect, the once daily treatment results in median decrease in total facial nodule lesion count (NLC) of at least 5. More preferably, the once daily treatment results in median decrease in total facial nodule lesion count (NLC) of at least 5.5. More preferably, the once daily treatment results in median decrease in total facial nodule lesion count (NLC) of 6. The results were assessed at 24 weeks.

[0045] In another aspect, the once daily treatment results in IGA score of clear or almost clear (IGA 0 / 1) in ≥90% of patients. More preferably, the once daily treatment results in IGA score of clear or almost clear (IGA 0 / 1) in ≥95% of patients. The results were assessed at 24 weeks.

[0046] In another aspect, the once daily treatment results in at least 90% reduction in inflammatory lesion count. More preferably, the once daily treatment results in at least 95% reduction in inflammatory lesion count. The results were assessed at 24 weeks.

[0047] In another aspect, the once daily treatment results in at least 90% reduction in non-inflammatory lesion count. More preferably, the once daily treatment results in at least 95% reduction in non-inflammatory lesion count. The results were assessed at 24 weeks.

[0048] In one embodiment of the above aspect, surfactants in the pharmaceutical composition include, but are not limited to, polysorbates prepared from lauric, palmitic, stearic, and oleic acid; polyoxyethylene monoesters such as polyoxyethylethylene monostearate, polyoxyethylene monolaurate, and polyoxyethylene monooleate; polyethoxylated castor oils (e.g., Cremophor® EL 35); polyethylene glycol glycerides (e.g., Gelucire® 44 / 14); vitamin E TPGS; dioctyl sodium sulfosuccinate; sodium lauryl sulfate; poloxamers; and mixtures thereof.

[0049] In another embodiment of the above aspect, the surfactant is present in an amount of about 1% w / w to about 99% w / w by total weight of the composition; preferably in an amount of about 10% w / w to about 80% w / w by total weight of the composition; more preferably in an amount of about 30% w / w to about 80% w / w by total weight of the composition.

[0050] In another embodiment of the above aspect, co-solvents in the pharmaceutical composition include, but are not limited to, propylene glycol, polypropylene glycol, polyethylene glycols, diethyleneglycol monoethyl ether, glyceryl caprylate, capric / caprylic glyceride, and mixtures thereof.

[0051] In another embodiment of the above aspect, the composition used for the method of treatment of acne further comprises an antioxidant.

[0052] The antioxidant includes, but is not limited to, butylated hydroxy anisole, butylated hydroxy toluene, tocopherol, ascorbyl palmitate, ascorbic acid, sodium metabisulfite, sodium sulfite, sodium thiosulfate, propyl gallate, and mixtures thereof.

[0053] Examples of suitable antioxidants include, but are not limited to, butylated hydroxyl anisole, butylated hydroxyl toluene, tocopherol, ascorbyl palmitate, ascorbic acid, sodium metabisulfite, sodium sulfite, sodium thiosulfate, propyl gallate, and mixtures thereof. The antioxidant is present in an amount of about 0.002% w / w to about 2% w / w of the total composition.

[0054] Examples of alkaline stabilizers include, but are not limited to, sodium hydroxide, potassium hydroxide, sodium carbonate or bicarbonate, potassium carbonate or bicarbonate, lithium hydroxide, triethylamine, meglumine, methylamine, and mixtures thereof.

[0055] Examples of suitable preservatives include, but are not limited to, methyl paraben, ethyl paraben, propyl paraben, butyl paraben, benzoic acid, sodium benzoate, benzyl alcohol, sorbic acid, potassium sorbate, and mixtures thereof.

[0056] In yet another embodiment, said oral pharmaceutical composition is stable when stored at 40° C. and 75% relative humidity or at 25° C. and 60% relative humidity for a period of at least three months or to the extent necessary for the use of the composition.

[0057] The term “stable,” as used herein, refers to chemical stability, wherein not more than 1.5% w / w of total related substances (excluding tretinoin) are formed on storage at accelerated conditions of stability at 40° C. and 75% relative humidity or at 25° C. and 60% relative humidity for a period of at least six months or to the extent necessary for use of the composition. Further, composition contains not more than 1% w / w 5, 6-epoxy-13-cis retinoic acid when stored at a temperature 40° C. and 75% relative humidity for a period of six months.

[0058] In one embodiment of the above aspect, the oral pharmaceutical composition is in the form of a dispersion which is further filled into capsules.

[0059] In yet another embodiment of the above aspect, the composition comprises isotretinoin wherein the particle size distribution of isotretinoin is such that D90 is less than 60 μm, less than 55 μm, less than 50 μm, less than 45 μm, less than 40 μm, less than 35 μm, less than 30 μm, less than 25 μm, less than 20 μm, less than 15 μm, or less than 10 μm.

[0060] In yet another embodiment of the above aspect, the composition comprises isotretinoin wherein the particle size distribution of isotretinoin is such that D90is less than 30 μm.

[0061] In another embodiment of the above aspect, the composition comprises isotretinoin wherein the particle size distribution of isotretinoin is such that D50is less than 40 μm, less than 35 μm, less than 30 μm, less than 25 μm, less than 20 μm, less than 15 μm, or less than 10 μm or less than 5 μm.

[0062] In yet another embodiment of the above aspect, the composition comprises isotretinoin wherein the particle size distribution of isotretinoin is such that D50is less than 15 μm.

[0063] In another embodiment of the above aspect, the composition comprises isotretinoin wherein the particle size distribution of isotretinoin is such that D10is less than 20 μm, less than 18 μm, less than 17 μm, less than 15 μm, less than 12 μm, less than 10 μm, less than 8 μm, less than 7 μm, less than 5 μm, or less than 2 μm.

[0064] In yet another embodiment of the above aspect, the composition comprises isotretinoin wherein the particle size distribution of isotretinoin is such that D10is less than 7 μm.

[0065] In yet another embodiment of the above aspect, the composition comprises isotretinoin wherein the particle size distribution of isotretinoin is such that D90 is less than 60 μm and D50is less than 40 μm.

[0066] In yet another embodiment of the above aspect, the pharmaceutical composition comprises isotretinoin wherein the particle size distribution of isotretinoin is such that D90 is less than 60 μm, D50is less than 40 μm, and D10is less than 20 μm.

[0067] In still another aspect, the present invention provides a method of treating acne, musculoskeletal and connective tissue inflammations, emphysema, ulcerating diseases, cervical tumors in HIV positive women, lung cancer in smokers, skin cancer, neuroblastoma, recurrent prostate cancer, leukemia, high-grade glioma, head and neck cancers, multiple myeloma, gram-negative folliculitis, recalcitrant rosacea, pyoderma faciale, psoriasis, cutaneous lupus erythematosus, acne fulminans, squamous cell carcinoma, or cutaneous photoaging by administering to the individual in need thereof the oral pharmaceutical composition of the present invention.

[0068] In some embodiments, the acne is acne vulgaris. In other embodiments, the acne is acne rosacea. In still other embodiments, the acne may be one or more of recalcitrant nodular acne, acne vulgaris, acne rosacea, acne conglobata, acne fulminans, gram-negative folliculitis, and pyoderma faciale. The acne may be a severe form of acne, a moderate form of acne, or a mild form of acne. More preferably, the acne is recalcitrant nodular acne.

[0069] In another aspect, the present invention provides a method of treating acne in a subject in need thereof wherein said method comprises administering isotretinoin in an amount of about 0.4 to about 1.6 mg per kilogram of the body weight; wherein the body weight of the subject and the selected dose correlate to one of the following:Body WeightTotal Daily Dosage (mg)0.4 mg / kg0.8 mg / kg1.6 mg / kg40 kg16326450 kg20408060 Kg24489670 Kg285611280 Kg326412890 Kg3672144

[0070] In another embodiment of the invention, the once daily administration of the above composition shows safety and efficacious for the treatment of acne

[0071] In one embodiment of the above aspect, the dose is given once daily for 15-20 weeks, more preferably for 20 weeks.

[0072] In one or more aspect of the present disclosure provides a method of treating acne comprising administering to the subject a pharmaceutical composition comprising:micronized isotretinoin having D90value of not more than 30 microns,one or more surfactants having HLB value of 10 or greater; andone or more co-solventswherein, the composition is, administered once daily to the subject under a fasting state, at a dose of about 0.4 mg / kg to about 1.6 mg / kg of isotretinoin for 20 weeks; and wherein the treatment results into a nodular lesion count reduction of ≥90% in >95% of patients.

[0073] In another aspect, the present disclosure provides a method of treating acne comprising administering to the subject a pharmaceutical composition comprising:micronized isotretinoin having D90 value of not more than 30 microns,one or more surfactants having HLB value of 10 or greater; andone or more co-solventswherein, the composition is administered once daily to the subject under a fasting state, at a dose of about 0.4 mg / kg to about 1.6 mg / kg of isotretinoin for 20 weeks and

[0074] wherein, the treatment results into Investigator Global Assessment (IGA) score of clear or almost clear (IGA 0 / 1) in at least 95% of patients when assessed at 24 weeks.

[0075] The term “Investigator Global Assessment (IGA)” refers to a scoring system in which the investigator will evaluate the IGA using the following scale and before assessing individual lesions counts:

[0076] Table 1 : Investigator Global Assessment Scale

[0077] In one or more aspect of the present disclosure provide, a method of treating acne comprising administering to the subject a pharmaceutical composition comprising:micronized isotretinoin having D90value of not more than 30 microns,one or more surfactants having HLB value of 10 or greater; andone or more co-solventswherein, the composition is, administered once daily to the subject under a fasting state, at a dose of about 0.4 mg / kg to about 1.6 mg / kg of isotretinoin; wherein the treatment results in mean percentage reduction in inflammatory and non- inflammatory lesion count of at least 95%.

[0078] The invention may be further illustrated by the following examples, which are for illustrative purposes only and should not be construed as limiting the scope of the invention in any way.

[0079] EXAMPLES:

[0080] Example 1:

[0081] The isotretinoin Capsules (ABSORICA LD®) contain 8 mg, 16 mg, 20 mg, 24 mg, 28 mg and 32 mg of micronized isotretinoin (a retinoid) in suspension filled in hard gelatin capsules for oral administration. In addition to the active ingredient, isotretinoin, USP each capsule contains the following inactive ingredients: butylated hydroxy anisole, gelatin, hard gelatin capsule shell, polysorbate 80 and soybean oil.

[0082] US 9,750,711 B2 exemplifies various composition of micronized isotretinoin the contents of which are incorporated herein.

[0083] Example 2: The Safety and Efficacy of Absorica LD® once daily without food in the treatment of recalcitrant nodular acne

[0084] The open label pilot study was conducted in 20 subjects ≥12 years of age with recalcitrant nodular acne. Key inclusion criteria were Investigator’s Global Assessment (IGA) score ≥4 and more than 5 facial nodules with a diameter ≥5 mm.

[0085] Subjects received micronized isotretinoin 0.4 to 0.8 mg / kg / day once daily without food for 20 weeks. The study comprised of 8 study visits: Screening, Baseline, and weeks 4, 8, 12, 16, 20 and 24.

[0086] All subjects will receive the micronized isotretinoin composition (Absorica LD) as once daily dosing (instead of receiving the label recommended dosing schedule of BID, subjects were given full daily dose) in fasting conditions for the full 20 weeks of therapy.

[0087] The evaluation was carried out on the basis of Investigator Global Assessment (IGA), total lesion count, inflammatory lesion count, non-inflammatory lesion count, adverse events and concomitant medications. A total of 24 subjects were enrolled, and 22 completed the study

[0088] The endpoints were assessed at end of 24week

[0089] Co-primaryend point-Change from baseline in total facial nodular lesion count (NLC) & Percentage of subjects reporting ≥90% reduction in NLC.

[0090] It was observed that the median (%) decrease from baseline in NLC at Week 24 was 6 (100%; P<0.0001). All 24 (100%) subjects achieved complete clearance of nodules (P<0.0001) ()

[0091] Secondaryend point-Percentage of subjects achieving an IGA score of clear or almost clear (IGA 0 / 1); Percentage reduction in inflammatory lesions; Percentage reduction in non-inflammatory lesions.

[0092] The percentage of subjects achieving IGA 0 / 1 increased at each follow-up visit and reached 96% (23 / 24 subjects) at Week 24 (P<0.0001)

[0093] Both inflammatory and non-inflammatory lesion counts significantly decreased from baseline at each follow-up visit ()–The mean ±SD percentage reductions at Week 24 were 97.8% ±5.7% (P<0.0001) for the inflammatory lesion count and 98.4% ±6.2% (P<0.0001) for the non-inflammatory lesion count

[0094] Safety and tolerabilitywere assessed from frequencies of adverse events and severity of erythema, dryness, peeling, oiliness, burning, and pruritus.

[0095] It was observed that the severity of erythema, dryness, and peeling increased slightly but significantly at early time points, no changes from baseline were observed in burning or pruritus, both of which were absent or minimal in most subjects.

[0096] Small, significant decreases in oiliness were observed at Weeks 4 and 20.

[0097] Table 3 - Summary of tolerability assessments through Week 24 Data

[0098] Thus, the treatment with micronized isotretinoin without food once daily for 20 weeks was well tolerated and highly efficacious in subjects ≥12 years of age with recalcitrant nodular acne

[0099] IGA and lesion counts (inflammatory, noninflammatory, and nodules) improved substantially at each follow-up visit, and the coprimary and all secondary endpoints were all met after 5 months

[0100] Treatment was well tolerated and safe, with small, minimal, early increases in erythema, dryness, and peeling, and no serious or treatment-related adverse events.

Claims

A method of treating acne comprising administering to the subject a pharmaceutical composition comprising:a) micronized isotretinoin having D90 value of not more than 30 microns,b) one or more surfactants having HLB value of 10 or greater; andc) one or more co-solvents,wherein, the composition is administered once daily to the subject under a fasting state, at a dose of about 0.4 mg / kg to about 1.6 mg / kg of isotretinoin.The method of claim 1 wherein, the subjects are ≥12 years of age.The method of claim 1, wherein the acne is selected from the group consisting of recalcitrant nodular acne, acne vulgaris, acne rosacea, acne conglobata, acne fulminans, gram-negative folliculitis, and pyoderma faciale.The method of claim 1, wherein the acne is recalcitrant nodular acne.The method according to claim 1 wherein, the pharmaceutical composition is administered to the subjects at the dose of isotretinoin as mentioned below.Body WeightTotal Daily Dosage (mg)0.4 mg / kg0.8 mg / kg1.6 mg / kg40 kg16326450 kg20408060 Kg24489670 Kg285611280 Kg326412890 Kg3672144The method of claim 1, wherein the once daily treatment results in ≥90% reduction in nodular lesion count in >95% of patients, when assessed at 24 weeks.The method of claim 1, wherein the once daily treatment results in median decrease in total facial nodule lesion count (NLC) of at least 5.5, when assessed at 24 weeks.The method of claim 1, wherein the once daily treatment results in IGA score of clear or almost clear (IGA 0 / 1) in at least 95% of patients, when assessed at 24 weeks.The method of claim 1, wherein the once daily treatment results in at least 95% reduction in inflammatory lesion count, when assessed at 24 weeks.The method of claim 1, wherein the once daily treatment results in at least 95% reduction in non-inflammatory lesion count, when assessed at 24 weeks.The method according to claim 1, wherein the particle size distribution of isotretinoin is such that D90 is less than 30 μm, less than 25 μm, less than 20 μm, less than 15 μm, or less than 10 μm.The method according to claim 1, wherein the particle size distribution of isotretinoin is such that D50, less than 20 μm, less than 15 μm, less than 10 μm, or less than 5 μm.The method according to claim 12, wherein the particle size distribution of isotretinoin is such that D50 is less than 15 μm.The method according to claim 1, wherein the particle size distribution of isotretinoin is such that D10 is less than 10 μm, less than 8 μm, less than 7 μm, less than 5 μm, or less than 2 μm.The method according to claim 14, wherein the particle size distribution of isotretinoin is such that D10 is less than 7 μm.The method according to claim 1, wherein the surfactant in the composition is selected from the group consisting of polysorbates prepared from lauric, palmitic, stearic, and oleic acid; polyoxyethylene monoesters; polyethoxylated castor oils; polyethylene glycol glycerides; Vitamin E TPGS; dioctyl sodium sulfosuccinate; sodium lauryl sulfate; poloxamers; and mixtures thereof.The method according to claim 16, wherein the surfactant in the composition is present in an amount of about 1% w / w to about 99% w / w by total weight of the composition.The method according to claim 17, wherein the surfactant is present in an amount of about 30% w / w to about 80% w / w by total weight of the composition.The method according to claim 1, wherein the co-solvent in the composition is selected from the group consisting of propylene glycol, polypropylene glycol, polyethylene glycols, diethyleneglycol monoethyl ether, glyceryl caprylate, capric / caprylic glyceride, and mixtures thereof.The method according to claim 1, wherein said composition further comprises an antioxidant.The method according to claim 20, wherein the antioxidant in the composition is selected from the group consisting of butylated hydroxy anisole, butylated hydroxy toluene, tocopherol, ascorbyl palmitate, ascorbic acid, sodium metabisulfite, sodium sulfite, sodium thiosulfate, propyl gallate, and mixtures thereof.The method according to claim 1, wherein said composition is in the form of a dispersion which is further filled into capsules.The method according to claim 1, wherein the pharmaceutical composition is administered once daily to the subjects for 15-20 weeks.The method according to claim 1, wherein the pharmaceutical composition is administered once daily to the subjects for 20 weeks.A method of treating of acne comprising administering to the subject a pharmaceutical composition comprising:a) micronized isotretinoin having D90value of not more than 30 microns,b) one or more surfactants having HLB value of 10 or greater; andc) one or more co-solvents,wherein, the composition is administered once daily to the subject under a fasting state, at a dose of about 0.4 mg / kg to about 1.6 mg / kg of isotretinoin for 20 weeks, and wherein, the treatment results into Investigator Global Assessment (IGA) score of clear or almost clear (IGA 0 / 1) in at least 95% of patients when assessed at 24 weeks.

Citation Information

Patent Citations

  • Pharmaceutical semi-solid composition of isotretinoin

    US7435427B2

  • Pharmaceutical semi-solid composition of isotretinoin

    US8367102B2

  • Oral pharmaceutical composition of isotretinoin

    US9700535B2

  • Low dose oral pharmaceutical composition of isotretinoin

    US9750711B2

  • Compositions of and process for producing isotretinoin having low particle size

    WO2000025772A1